There are three ongoing ICI Trials testing optimal perturbation of the tumor immune system and rate of pathologic response, this are the NESCIO trial, the SPARC-1 and NAPSTER. The NESCIO trial ...
Researchers report significant progress toward expanding the therapeutic options available for people with non-cancerous blood conditions in five studies presented during the 66th American Society of ...
In the pivotal LUNA 3 study, adult patients with persistent or chronic ITP and severely low platelet counts (median of 15,000/μL) received oral rilzabrutinib 400 mg twice a day (n=133) or placebo ...
(UroToday.com) The 2024 SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Eric Jonasch discussing a phase 1B/2 study of combination 177 Lu Girentuximab + ...